Azurity Pharmaceuticals vs. Novitium Pharma: Enalapril Patent Case Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Azurity Pharmaceuticals, Inc. v. Novitium Pharma, LLC |
| Case Number | 1:23-cv-00163 |
| Court | U.S. District Court, District of Delaware |
| Duration | Feb 2023 – Apr 2024 1 year 2 months |
| Outcome | Stipulated Dismissal — Case Closed |
| Patents at Issue | |
| Accused Products | Novitium Enalapril Maleate Oral Solution |
Case Overview
In a case that underscores the strategic complexity of pharmaceutical patent litigation, Azurity Pharmaceuticals, Inc. v. Novitium Pharma, LLC (Case No. 1:23-cv-00163) concluded not with a bench ruling or jury verdict, but with a stipulated dismissal—one of the more tactically significant outcomes in enalapril maleate oral solution patent infringement disputes. Filed in the Delaware District Court on February 14, 2023, and formally closed on April 8, 2024, after 419 days, this case involved two patents protecting a ready-to-use oral enalapril maleate solution and raised questions about ANDA-related pharmaceutical patent enforcement that resonate well beyond a single docket.
For patent litigators, IP professionals, and pharmaceutical R&D teams, stipulated dismissals in Hatch-Waxman-adjacent litigation are rarely simple concessions. They often reflect carefully negotiated resolutions shaped by parallel proceedings, commercial pressures, and claim exposure across multiple dockets. This case is no exception.
The Parties
⚖️ Plaintiff
A specialty pharmaceutical company focused on novel drug formulations, particularly oral solutions and suspensions for underserved patient populations. Its IP portfolio reflects a deliberate strategy of protecting reformulated drug products through layered patent coverage.
🛡️ Defendant
A New Jersey-based generic pharmaceutical manufacturer with an active pipeline of ANDA filings targeting branded drug formulations. As a generic entrant, Novitium routinely faces patent challenges from branded pharmaceutical holders asserting exclusivity over proprietary formulations.
Patents at Issue
This landmark case involved two U.S. patents covering fundamental pharmaceutical formulation elements. Patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect compositions and methods centered on stable, ready-to-use oral enalapril maleate solutions.
- • US 11,040,023 B2 — Directed to formulations and methods related to enalapril maleate oral solutions.
- • US 11,141,405 B2 — Similarly directed to enalapril maleate liquid formulation technology.
Developing a similar pharmaceutical formulation?
Check if your product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
On April 8, 2024, Chief Judge Mitchell S. Goldberg ordered the Clerk of Court to mark Case No. 23-cv-163 as closed, following the stipulated dismissal of all claims against Novitium Pharma LLC. The closing order references Doc. No. 436 in Case No. 21-cv-1286, indicating this action was one of at least two parallel or related proceedings involving the same parties or patents.
No damages amount was disclosed, and no injunctive relief was referenced in the available case record. The precise terms of any underlying settlement or licensing agreement between the parties were not made part of the public record. The verdict cause is classified as an Infringement Action, and the basis of termination is a **stipulated dismissal**.
Key Legal Issues
Delaware’s District Court remains the preeminent forum for pharmaceutical patent litigation, particularly cases with Hatch-Waxman dimensions. The court’s deep familiarity with ANDA litigation, claim construction standards, and pharmaceutical formulation patents makes venue selection here a deliberate strategic choice by branded pharmaceutical plaintiffs.
A document numbered in the 400s (Doc. No. 436 in 21-cv-1286) suggests substantial prior litigation activity—including likely claim construction briefing, expert reports, and potentially summary judgment motions—in the companion proceeding. Resolution in that docket effectively resolved the dispute in this case as well. This outcome frequently signals one of several underlying realities: a confidential settlement, resolution of a companion case rendering this one moot, or strategic recalibration by either party based on litigation developments.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulation development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic space
- See which companies are most active in similar formulation patents
- Understand claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Enalapril maleate liquid formulations
2 Patents Asserted
Covering oral solution technology
ANDA Litigation Context
Specialized legal considerations
✅ Key Takeaways
Stipulated dismissals linked to companion dockets require careful monitoring of all parallel proceedings simultaneously.
Search related case law →Multi-patent assertion strategies in pharmaceutical litigation create settlement leverage across the portfolio.
Explore precedents →Delaware remains the dominant forum for formulation patent disputes; local counsel selection is strategically critical.
View firm IP dockets →Frequently Asked Questions
Two patents were asserted: U.S. Patent No. 11,040,023 B2 and U.S. Patent No. 11,141,405 B2, both covering enalapril maleate ready-to-use oral solution formulations.
All claims were dismissed by stipulation of the parties, linked to resolution activity in companion Case No. 21-cv-1286. No merits determination was issued.
Azurity’s asserted patents remain unchallenged on the merits by this dismissal, preserving their enforceability against future generic market entrants.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the District of Delaware — Case 1:23-cv-00163
- U.S. Patent No. 11,040,023 B2
- U.S. Patent No. 11,141,405 B2
- U.S. Patent and Trademark Office — Patent Resources
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.